FDA Approves Xarelto To Reduce Risk Of Blood Clots
On July 1, the U.S. Food and Drug Administration approved Xarelto ( rivaroxaban ) to reduce the risk of blood clots, deep vein thrombosis ( DVT ), and pulmonary embolism (PE) following knee or hip replacement surgery.
Minimizing Adverse Reactions by Stopping the Bleeding
Patients with acute coronary syndromes often must resort to stents or balloon angioplasty to relieve artery constriction. Now the European Society of Cardiology is suggesting new strategies to minimize bleeding during such procedures.
New Findings on Hormone Replacement Therapy
You may remember some years ago when a large women's study was stopped because one of the therapies being tested was shown to actually increase the risk of breast cancer, heart attacks and strokes.